




# Gene Expression in Eukaryotes

## 真核生物基因表达调控

复旦大学分子医学教育部重点实验室

马 端



25-28w




24w




13-16w



9-12w




29-32w



8w



Fertilization



zygote



4w



7w

# Regulation Points of Gene Expression

**Chromatin Activation**

**Transcription**


**Post-transcriptional Modification**

**RNA Transport**

**Translation**




**RNA degradation**

**Post-translational modifications**




# Chromatin Activation

## 染色质活化





# Chromatin-remodeling Complexes

## 染色质重塑复合物




Structure of nucleosome (核小体)

### ATP-DEPENDENT CHROMATIN REMODELING




# Control of Transcription Initiation

## 转录起始调控



# Some Cis-elements in Promotor



**TATA box** (TATAAAA ) is at -25 and is involved in positioning the enzyme for correct initiation.


**GC box** is at -90 contains the sequence GGGCGG and is recognized by the factor SP1.

**CAAT box** (CCAATCT) is at -75 and is recognized by a large group of transcription factors and plays a strong role in determining the efficiency of the promoter.




# Transcription Factors (转录因子)

**Transcription factor** (sequence-specific DNA binding factor) is a protein that binds to specific sequences of DNA and thereby controls the transfer (or transcription) of genetic information from DNA to RNA.




TATA binding protein



**General Transcription Factor**

T7 RNA polymerase

**Specific Transcription Factor**





# Structure of Transcription Factors

- **DNA-binding domain(DBD)**: attach to specific sequences of DNA.
- **Trans-activating domain (TAD)**: contain binding sites for other proteins.
  - **glutamine-rich activation domains**
  - **proline-rich activation domains**
  - **acidic activation domains**
- **Signal sensing domain (SSD)** (ligand binding domain) which senses external signals and in response transmit these signals to the rest of the transcription complex resulting in up or down regulation of gene expression.
- **Protein-protein interaction domain**



# Basic helix-loop-helix (bHLH)

## 碱性螺旋—环—螺旋基序



bHLH structural motif (模体, 基序) : two  $\alpha$  helices connected by a loop



Structural motif: a pattern in a protein structure formed by the spatial arrangement of amino acids.

In general, transcription factors including this domain are dimeric, each with one helix containing basic amino acid residues that facilitate DNA binding.

bHLH proteins typically bind to a consensus sequence called an E-box which is [CACGTG](#), however some bHLH transcription factors bind to different sequences, which are often similar to the E-box.

# Basic Leucine Zipper Domain (bZIP domain)

## 碱性亮氨酸拉链结构域




Protein domain: an autonomously folding functional module of a protein.

One part of **bZIP domain** contains a region that mediates sequence specific DNA binding properties and the leucine zipper that is required for the dimerization of two DNA binding regions. The DNA binding region comprises a number of basic aminoacids such as arginine and lysine.

# helix-turn-helix (HTH)



螺旋－回折－螺旋



**HTH** is composed of two  $\alpha$  helices joined by a short strand of amino acids. Recognition and binding to DNA is done by the two  $\alpha$  helices. One  $\alpha$  helices binds to the major groove of DNA through a series of hydrogen bonds and various Van der Waals interactions with exposed bases. The other  $\alpha$  helix stabilizes the interaction between protein and DNA, but does not play a particularly strong role in its recognition.

# Zinc Finger

## 锌指




A zinc finger consists of two antiparallel  $\beta$  strands, and an  $\alpha$  helix. The zinc ion is crucial for the stability. Transcription factors with zinc fingers interact with the major groove along the double helix of DNA in which case the zinc fingers are arranged around the DNA strand in such a way that the  $\alpha$ -helix of each finger contacts the DNA, forming an almost continuous stretch of  $\alpha$ -helices around the DNA molecule.

### Activators

These proteins bind to genes at sites known as *enhancers*. Activators help determine which genes will be switched on, and they speed the rate of transcription.

### Repressors

These proteins bind to selected sets of genes at sites known as *silencers*. They interfere with the functioning of activators and thus slow transcription.



### Coactivators



These "adapter" molecules integrate signals from activators and perhaps repressors and relay the results to basal factors.

### Basal transcription factors

In response to injunctions from activators, these factors position RNA polymerase at the start of the protein-coding region of a gene and send the enzyme on its way.

# DNA Methylation

## DNA 甲基化



DNA methylation is the covalent addition of a methyl group (CH<sub>3</sub>) to cytosine within the context of CpG dinucleotide (CpG island).











Representation of a Gene




DNA Methylation is a modification of one of DNA's four bases: cytosine. This is represented with the addition of the "M" symbol for the methyl group.



Dnmt1



Dnmt2



Dnmt3a




Dnmt3b





Dnmt3L

PMID: 11719692




## DNA Methyltransferases, DNA 甲基转移酶







The flipping out of the Cytosine by the methyltransferase from the DNA duplex.

# Post-transcriptional Modification





**Post-transcriptional modification** is a process in eukaryotic cells by which primary transcript RNA is converted into mature RNA.

# Capping



Capping of the pre-mRNA involves the addition of **7-methylguanosine (m<sup>7</sup>G)** to the 5' end which is called a **cap 0 structure**. The ribose of the adjacent nucleotide may also be methylated to give a **cap 1**. Methylation of nucleotides downstream of the RNA molecule produce **cap 2**, **cap 3** structures and so on. The cap protects the 5' end of the primary RNA transcript from attack by ribonucleases.


# Cleavage and Polyadenylation



The pre-mRNA processing at the 3' end of the RNA involves cleavage and the addition of about 200 adenine residues to form a poly(A) tail.

Cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CStF) are two factors that bind to the sequence elements. A protein complex forms which contains additional cleavage factors and the enzyme Polyadenylate Polymerase (PAP). This complex cleaves the RNA between the polyadenylation sequence and the GU-rich sequence at the cleavage site. Poly(A) polymerase then adds about 200 adenine units to the new 3' end of the RNA molecule using ATP as a precursor. As the poly(A) tail is synthesized, it binds multiple copies of poly(A) binding protein, which protects the 3' end from ribonuclease digestion.


# Alternative RNA Splicing



In many cases, the splicing process can create a range of unique proteins by varying the exon composition of the same messenger RNA. This phenomenon is then called alternative splicing. Exons can be extended or skipped, or introns can be retained.






# RNA Editing




**RNA editing** describes those molecular processes in which the information content in an RNA molecule is altered through a chemical change in the base makeup. RNA editing in mRNAs effectively alters the amino acid sequence of the encoded protein.

# mRNA Degradation




# Translation Control

## 翻译调控



# Phosphorylation of eIF2 Regulates Synthesis of Protein


eIF2 (Eukaryotic Initiation Factor 2) is an eukaryotic initiation factor. It is required in the initiation of translation.




Protein phosphorylation plays an important role in the control of eIF2. eIF2 binds GTP and Met-tRNA and transfers the Met-tRNA to the 40S subunit to form the 43S pre-initiation complex. Later in the cycle, prior to elongation, the bound GTP is hydrolyzed, releasing eIF2-GDP. For eIF2 to promote another round of initiation, GDP must be exchanged for GTP, a reaction catalyzed by eIF2B. This phosphorylation stabilizes the eIF2-GDP-eIF2B complex, inhibiting the turnover of eIF2B.

# Leaky Scanning


## 易遗漏扫描



Leaky scanning is a way to translate two overlapping open reading frames (ORF) on the same mRNA independently of each other.



When the small ribosome subunit reaches the first AUG codon it may recruit the large subunit and initiate translation of the first ORF.



However, the nucleotides surrounding the AUG codon may disturb this process and the small subunit will then continue to the next AUG codon and initiate translation of ORF-2.

In this way two independent proteins can be expressed from a relatively small genomic region.





Leaky scanning is also used to express a protein encoded downstream of the first ORF on the mRNA.

# Posttranslational Modification

**Posttranslational modification** (PTM) is the chemical modification of a protein after its translation.


After translation, the posttranslational modification of amino acids extends the range of functions of the protein by attaching to it other biochemical functional groups such as acetate, phosphate, various lipids and carbohydrates, by changing the chemical nature of an amino acid or by making structural changes, like the formation of disulfide bridges.

# Post-translational Modifications of Histones



Acetylation: 乙酰化; Methylation: 甲基化; Phosphorylation: 磷酸化; Ubiquitination: 泛素化

# Modification of Primary Structure of Insulin






# Structure and Function of TFPI-2

MW: 25KD


AA: 235



Most In ECM




- **Physiological role**
  - Unclear
- **Inhibits many tumors invasion**
  - Gliomas, Fibrosarcoma, Melanoma, Lung cancer, Prostate cancer, etc.
- **Inhibits atherosclerosis plaques rupture.**
- **Target diseases**
  - Malignant Tumor metastasis
  - Unstable ungina
  - Acute pancreatitis

# Expression of TFPI-2 in Breast Cancer Sample






1 2 3 4 5



HUVEC: T -839 C;  
MCF-7: G -1196 C;  
C -735 G;  
C -702 T;  
G -467 C

MDA-MB-231:  
A -1222 G;  
T -876 --;  
C -463 T



MDA-MB-435:  
A -1100 G;  
A -1077 C;  
A -1072 T;  
A -1059 G;  
T -876 --;  
T -859 C;  
A -811 G;  
A 13 G



435 435 231 231 M7 M7 EC EC M

1344 AGTAATAAGA CATTGTGTAT ATATTAGAAT ATTACTCAAT GATT1AAAAG AACAGACTAT Normal.  
1344 AGTAATAAGA CATTGTGTAT ATATTAGAAT ATTACTCAAT GATT1AAAAG AACAGACTAT HUVEC.  
1344 AGTAATAAGA CATTGTGTAT ATATTAGAAT ATTACTCAAT GATT1AAAAG AACAGACTAT MCF-7.  
1344 AGTAATAAGA CATTGTGTAT ATATTAGAAT ATTACTCAAT GATT1AAAAG AACAGACTAT 231.  
1344 AGTAATAAGA CATTGTGTAT ATATTAGAAT ATTACTCAAT GATT1AAAAG AACAGACTAT 435.  
1284 TGATACAGAC AGCAACATAT TTATACATTG TGGGATATTC ATACGTTTTA TATTACTCAA Normal.  
1284 TGATACAGAC AGCAACATAT TTATACATTG TGGGATATTC ATACGTTTTA TATTACTCAA HUVEC.  
1284 TGATACAGAC AGCAACATAT TTATACATTG TGGGATATTC ATACGTTTTA TATTACTCAA MCF-7.  
1284 TGATACAGAC AGCAACATAT TTATACATTG TGGGATATTC ATACGTTTTA TATTACTCAA 231.  
1284 TGATACAGAC AGCAACATAT TTATACATTG TGGGATATTC ATACGTTTTA TATTACTCAA 435.  
1224 TGATTTAAAG GAACAGACTA TTGATACAGA CAGCAACATA TTATACATT GTGGGATATT Normal.  
1224 TGATTTAAAG GAACAGACTA TTGATACAGA CAGCAACATA TTATACATT GTGGGATATT HUVEC.  
1224 TGATTTAAAG GAACAGACTA TTGATACAGA CAGCAACATA TTATACATT GTGGGATATT MCF-7.  
1224 TGATTTAAAG GAACAGACTA TTGATACAGA CAGCAACATA TTATACATT GTGGGATATT 231.  
1224 TGATTTAAAG GAACAGACTA TTGATACAGA CAGCAACATA TTATACATT GTGGGATATT 435.  
1164 CATACGTTTT GGTAAATCA TACCTTGGAC TACGCAGGAA TAAAAGAAA CAGACTATTG Normal.  
1164 CATACGTTTT GGTAAATCA TACCTTGGAC TACGCAGGAA TAAAAGAAA CAGACTATTG HUVEC.  
1164 CATACGTTTT GGTAAATCA TACCTTGGAC TACGCAGGAA TAAAAGAAA CAGACTATTG MCF-7.  
1164 CATACGTTTT GGTAAATCA TACCTTGGAC TACGCAGGAA TAAAAGAAA CAGACTATTG 231.  
1164 CATACGTTTT GGTAAATCA TACCTTGGAC TACGCAGGAA TAAAAGAAA CAGACTATTG 435.  
1104 ATGCAGTGAC CTGGGCGTAT CTCAAAAACA GGAAGTGTGA GAAAGAATA CTACACAGTG Normal.  
1104 ATGCAGTGAC CTGGGCGTAT CTCAAAAACA GGAAGTGTGA GAAAGAATA CTACACAGTG HUVEC.  
1104 ATGCAGTGAC CTGGGCGTAT CTCAAAAACA GGAAGTGTGA GAAAGAATA CTACACAGTG MCF-7.  
1104 ATGCAGTGAC CTGGGCGTAT CTCAAAAACA GGAAGTGTGA GAAAGAATA CTACACAGTG 231.  
1104 ATGCAGTGAC CTGGGCGTAT CTCAAAAACA GGAAGTGTGA GAAAGAATA CTACACAGTG 435.  
924 CTGCAGGAGC TTCTGGAGT GATGAAATG TTCTAACTCT TTTTTTTTC TTCTTCTCT Normal.  
924 CTGCAGGAGC TTCTGGAGT GATGAAATG TTCTAACTCT TTTTTTTTC TTCTTCTCT HUVEC.  
924 CTGCAGGAGC TTCTGGAGT GATGAAATG TTCTAACTCT TTTTTTTTC TTCTTCTCT MCF-7.  
924 CTGCAGGAGC TTCTGGAGT GATGAAATG TTCTAACTCT TTTTTTTTC TTCTTCTCT 231.  
924 CTGCAGGAGC TTCTGGAGT GATGAAATG TTCTAACTCT TTTTTTTTC TTCTTCTCT 435.  
864 TCTTTTCTT CGTTTCGAGA CCGAGTTCCA CTCTGCCGCC CAGACTGGAG TGCAGTGGCG Normal.  
924 TCTTTTCTT CGTTTCGAGA CCGAGTTCCA CTCTGCCGCC CAGACTGGAG TGCAGTGGCG HUVEC.  
924 TCTTTTCTT CGTTTCGAGA CCGAGTTCCA CTCTGCCGCC CAGACTGGAG TGCAGTGGCG MCF-7.  
924 TCTTTTCTT CGTTTCGAGA CCGAGTTCCA CTCTGCCGCC CAGACTGGAG TGCAGTGGCG 231.  
924 TCTTTTCTT CGTTTCGAGA CCGAGTTCCA CTCTGCCGCC CAGACTGGAG TGCAGTGGCG 435.  
744 CCCGAGGGGC TGGGACTACA GGTGCCGCC ACCACGCCGC GCTAATTTTT TGTGTTTTTA Normal.  
744 CCCGAGGGGC TGGGACTACA GGTGCCGCC ACCACGCCGC GCTAATTTTT TGTGTTTTTA HUVEC.  
744 CCCGAGGGGC TGGGACTACA GGTGCCGCC ACCACGCCGC GCTAATTTTT TGTGTTTTTA MCF-7.  
744 CCCGAGGGGC TGGGACTACA GGTGCCGCC ACCACGCCGC GCTAATTTTT TGTGTTTTTA 231.  
744 CCCGAGGGGC TGGGACTACA GGTGCCGCC ACCACGCCGC GCTAATTTTT TGTGTTTTTA 435.  
504 TACGATATAT TATAAGCCTG TATTAATGT AAATTAGAAC TCGATTGAAA TCTGTGTGTA Normal.  
504 TACGATATAT TATAAGCCTG TATTAATGT AAATTAGAAC TCGATTGAAA TCTGTGTGTA HUVEC.  
504 TACGATATAT TATAAGCCTG TATTAATGT AAATTAGAAC TCGATTGAAA TCTGTGTGTA MCF-7.  
504 TACGATATAT TATAAGCCTG TATTAATGT AAATTAGAAC TCGATTGAAA TCTGTGTGTA 231.  
504 TACGATATAT TATAAGCCTG TATTAATGT AAATTAGAAC TCGATTGAAA TCTGTGTGTA 435.  
24 GCGGGCACCC GGGCCGCTG GAGCAGAAA CCGCGCACCT CTTCCGCCA GGCCTTTCT Normal.  
24 GCGGGCACCC GGGCCGCTG GAGCAGAAA CCGCGCACCT CTTCCGCCA GGCCTTTCT HUVEC.  
24 GCGGGCACCC GGGCCGCTG GAGCAGAAA CCGCGCACCT CTTCCGCCA GGCCTTTCT MCF-7.  
24 GCGGGCACCC GGGCCGCTG GAGCAGAAA CCGCGCACCT CTTCCGCCA GGCCTTTCT 231.  
24 GCGGGCACCC GGGCCGCTG GAGCAGAAA CCGCGCACCT CTTCCGCCA GGCCTTTCT 435.

# Variation of DNA sequence in promoter region has no significant effect on it's activity





# Methylation Difference in CpG Island

-177	GGCAGGTTCA	ACTTTTCAAC	TTGGCGGGGA	ATTCTCTCC	CTCTTACACA	GTTTGCAGCG
MDA-MB-435	-----	-----	----- <sup>c<sup>m</sup></sup> -----	-----	-----	----- <sup>c<sup>m</sup></sup> -----
MCF-7	-----	-----	-----C-----	-----	-----	-----C-----
-117	CGGGGGCGGC	GGGGTGACAG	TCCCCGTGCA	TGAATCAGCC	ACCCCTCAGG	CTCCGCCCCG
MDA-MB-435	<sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> -----	-----	----- <sup>c<sup>m</sup></sup> -----	-----	-----	----- <sup>c<sup>m</sup></sup> -----C-----
MCF-7	C-----C-----C-----	-----	-----C-----	-----	-----	-----C-----C-----
-57	GCGGGGGTCTG	GCCGGACGCT	CGCCCCGCAT	AAAGCGGGCA	CCCGGGCCGC	CTGGAGCAGA
MDA-MB-435	-C----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> -----	<sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> -----	-----
MCF-7	-C-----C-----	-----C-----C-----	C-----C-----	-----C-----	-----C-----C-----	-----
+4	AAGCCGCGCA	CCTCCTCCC	CCAGGCGCTT	TCTCGGACGC	CTTGCCAGC	GGGCCGCCG
MDA-MB-435	----- <sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----C-----
MCF-7	-----C-----C-----	-----C-----	-----C-----	-----C-----	-----C-----	-----C-----C-----
+64	ACCCCTGCA	CCATGGACCC	CGCTCGCCCC	CTGGGGCTGT	CGATTCTGCT	GCTTTTCCTG
MDA-MB-435	-----	-----	C-----C-----	-----	C-----	----- <sup>c<sup>m</sup></sup> -----
MCF-7	-----	-----	C-----C-----	-----	C-----	-----C-----
+124	ACGGAGGCTG	CACTGGGCGA	TGCTGCTCAG	GAGCCAACAG	GTATCTGGCC	GCTCCAGGAG
MDA-MB-435	- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----	-----	-----	----- <sup>c<sup>m</sup></sup> -----	-----
MCF-7	-C-----	-----C-----	-----	-----	-----C-----	-----
+184	CTTCTCTCCC	CAACCGGCGG	AGAGGGCGCA	GCGGGCCATG	GGGCCCCGTG	TAGGCGCCCT
MDA-MB-435	-----	----- <sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----	-C-----	----- <sup>c<sup>m</sup></sup> -----	----- <sup>c<sup>m</sup></sup> -----
MCF-7	-----	-----C-----C-----	-----	-C-----	-----C-----	-----C-----
+244	CCAAGCCTCG	CTTTCTCCAG	GTCCCTGCCG	CGCGCTCCGC	TGGCAGGGGG	GACTCGCTCC
MDA-MB-435	----- <sup>c<sup>m</sup></sup> -----	-----	----- <sup>c<sup>m</sup></sup> -----	<sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> ----- <sup>c<sup>m</sup></sup> -----	-----	-----C-----
MCF-7	-----C-----	-----	-----C-----	C-----C-----C-----	-----	-----C-----
+304	CAAGTTTGCA	CTTTCTCTGC	AGAGGCCCCCT	CCGCTCGGAA	GGGGACAGAA	CTCCC
MDA-MB-435	-----	-----	-----	- <sup>c<sup>m</sup></sup> -----C-----	-----	-----
MCF-7	-----	-----	-----	-C-----C-----	-----	-----

bisulfite sequencing PCR

# Effect of 5-AZA(DNMT inhibitor), TSA(HDAC inhibitor) on the mRNA and protein expression of TFPI-2




5-AZA( $\mu$ M)	-	-	1.25	1.25	2.5	2.5	5.0	5.0
	-	+	-	+	-	+	-	+

	-	-	1.25	1.25	2.5	2.5	5.0	5.0
	-	+	-	+	-	+	-	+





# P-144 has nearly same luciferase activity as P-1436







# Methylation Represses TFPI-2 Promoter Activity In Vitro



# Scanning Mutation


-84 ~ -36 was essential



TFs	Opt.	Position.	S.	C.m.	M.m	Sequence
AP1	0.95	-89 to -79	(+)	0.884	0.971	catgaATCAgc
<b>KLF6</b>	0.87	-86 to -64	(+)	0.923	0.875	gaatcagCCACcctcaggctcc
<b>KLF6</b>	0.87	-72 to -50	(+)	1	0.908	tcaggctCCGcccggcgggggt
<b>SP1</b>	0.88	-70 to -56	(-)	1	0.942	gccggGGCGgagcct
AP2	0.89	-63 to -51	(-)	1	0.895	ccCCCGccggggc


## Searching Transcription Factor Binding Sites

# Binding of KLF6 Was BLocked by DNA Methylation



**A: MCF-7**

**B: MDA-MB-435**



**-86**

**KLF6**


**SP1**

**-42**

5'-GAATCAGCCACCCCTCAGGCTCC<sup>m</sup>GCCCCGGCGGGGGTTCGGCCGGA-3';  
 3'-CTTAGTCGGTGGGGAGTCCGAGGC<sup>m</sup>GGGGCCGCCCCCAGCCGGCCT-5'

# Summary

- Chromatin Activation
- Control of Transcription Initiation: cis-elements, transcription factor
- Post-transcription modification: capping, polyadenylation, alternative mRNA splicing, RNE editing, mRNA degradation
- Post-translational Control: protein modification
- An example of Epigenetic regulation



**The two main components of the epigenetic code**

**DNA methylation**

Methyl marks added to certain DNA bases repress gene activity.

**Histone modification**

A combination of different molecules can attach to the 'tails' of proteins called histones. These alter the activity of the DNA wrapped around them.

*Try not to become a man of success but rather try to become a man of value.*

*-- A. Einstein*